The European Medicines Agency (EMA) said on Friday it expected to receive "
soon
" an application for conditional marketing authorization in the EU for the vaccine against Covid-19 developed by Johnson & Johnson.
Read also: Covid-19: the Johnson & Johnson vaccine 66% effective in general, less in South Africa
"
We have just heard some promising results from the Janssen vaccine, with the hope that it will be submitted to us soon,
" Emer Cooke, executive director of the Amsterdam-based EMA, told a conference. press online.
Johnson & Johnson announced on Friday that its vaccine was 66% effective against Covid-19.
“
J & J's
”
vaccine
is currently undergoing “
continuous review
”, which allows the EMA to review vaccine safety and efficacy data as they become available, even before an application. formal authorization is filed by the manufacturer.
The European regulator on Friday approved the use in the European Union of the AstraZeneca / Oxford vaccine, after giving the green light for those of Pfizer / BioNTech on December 21 and Moderna on January 6.
